Walter Matthew R. sold $258K of MDT

Walter Matthew R. (SVP, Chief HR Officer) sold 3,102 shares of Medtronic plc (MDT) at $83.15 ($0.26M total) on 2026-07-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Walter Matthew R.
Published Jul 9, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 8:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MDT
Neutral
high confidence
Mentioned
$MDT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDTNeutralLow
01

Why it matters

The disclosed sale is a concrete datapoint for insider activity, but it does not introduce new company-specific fundamentals (no guidance, trial, deal, or regulatory action).

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure makes it less actionable for directional fundamental trades.

03

What to watch

The article does not state whether sales were part of a broader pattern, nor does it provide options activity or other holdings changes beyond the post-transaction share count.

Relevance 3/10Novelty 2/10Timing: new Form 4 filed July 9, covering a July 8 sale

Background

This is an SEC Form 4 insider transaction disclosure for Medtronic plc, reported as an open-market sale under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$MDTNeutralHigh confidence
Context

Medtronic insider Walter Matthew R., SVP Chief HR Officer, sold 3,102 shares for about $257,931 under a 10b5-1 plan on July 8.

Expected impact

Likely minimal impact on MDT price; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider sale with a pre-arranged 10b5-1 plan, and the article provides no accompanying operational or financial catalyst.

Market effects

No clear read-across to medtech sector fundamentals from a single routine insider sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can reflect personal liquidity needs or risk management, which some traders may still fade.

Key entities

  • Medtronic plc

    MDT, subject of the Form 4 insider transaction disclosure.

  • Walter Matthew R.

    SVP, Chief HR Officer who sold 3,102 shares on July 8 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDTMed

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

Medtronic (NYSE: MDT) received FDA clearance for its Hugo™ robotic-assisted surgery system to perform general surgery procedures, including cholecystectomy and hernia repairs. The expansion covers 3.5 million annual U.S. surgeries. The system's modular design offers flexibility, and Medtronic aims to surpass 50,000 procedures globally by its fiscal year-end.

$MDTMedAI 8/10

Medtronic buys Contego Medical for $380 M, expanding access to next-generation carotid therapies

Medtronic plans to acquire Contego Medical for $380 million, expanding its carotid artery disease treatment portfolio. The deal includes Contego's FDA-approved Neuroguard IEP™ Direct System. Medtronic expects the acquisition to be minimally dilutive to adjusted EPS in FY27 and FY28, and neutral to accretive thereafter. The transaction is subject to closing conditions and expected to complete in Q3 FY25.

$MDTMedAI 9/10

Medtronic agrees to buy carotid stent maker Contego Medical for $380 million

Medtronic agreed to acquire Contego Medical for $380 million, with potential additional payments. The deal includes Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices. Medtronic expects the acquisition to close in its fiscal third quarter, with minimal EPS dilution in fiscal 2027 and 2028, and a neutral to accretive effect afterward. Contego's devices focus on carotid artery disease and peripheral thrombectomy.